news, humanized monoclonals......
* CENTOCOR INC plans to launch Remicade, approved in August for
treating Chrohn's disease, for the treatment of rheumatoid
arthritis in late 1999 in the U.S. and the second half of 2000 in
Europe. David Holveck, president and CEO of Centocor told
investors that Remicade reached its first Crohn's disease patient
late last week. Centocor plans to file for approval of the
rheumatoid arthritis indication in the United States late this
year or in the 1Q of 1999. Holveck repeated a previous statement
that the company planned to announce data from Phase 3 studies for
the rheumatoid arthritis indication in November. Holveck said the
company plans to launch Remicade for Chrohn's disease in Europe in
the first half of 1999. (Reuters 10:18 AM ET 10/06/98)
and, from BGEN's sparkling release yesterday, anti-CD40L now has a name, "Antova" (thanks, Peter).........
Jim Tobin, Biogen's Chief Executive Officer, said.......
"We continue to make excellent progress with our development
pipeline,
which includes AMEVIVE(TM) (human LFA-3/IgG fusion protein) for
psoriasis, ANTOVA(TM) (humanized CD40 Ligand antibody/5c8) for
autoimmune disease and CVT-124 for congestive heart failure. We have
a number of clinical trials underway and will begin to have results of
several Phase II trials in early 1999."
|
